ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1081

Patient-reported Outcomes in Early Autoimmune Inflammatory Myopathies

Valérie Leclair1, Brett Thombs2, Mianbo Wang3, Evelyne Vinet4, Alexandra Albert5 and Marie Hudson6, 1Division of Rheumatology, Jewish General Hospital, Montreal, QC, Canada, 2Department of Psychology, McGill University, Montreal, QC, Canada, 3Lady Davis institute for Medical Research, Montreal, QC, Canada, 4McGill University Health Center, Montreal, QC, Canada, 5Division of Rheumatology, Centre Hospitalier de l’Université Laval, Québec, QC, Canada; Department of Medicine, Université Laval, Québec, QC, Canada., Neuville, Canada, 6Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada

Meeting: ACR Convergence 2020

Keywords: Disability, Fatigue, Myositis, Patient reported outcomes, quality of life

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: Muscle Biology, Myositis & Myopathies Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Patient-reported outcomes (PROs) are increasingly used in rheumatology. Such outcomes are under-reported in autoimmune inflammatory myopathies (AIM) especially in incident cohorts. The objective of this study was to explore physical function, fatigue, depressive symptoms, sleep quality and health-related quality of life (HRQoL) in early AIM, and the effect of disease activity on those domains.

Methods: Cross-sectional study of adult AIM subjects with disease duration of <2 years enrolled in a multicenter research cohort. Standardized clinical histories, medical examinations, and self-administered questionnaires were collected at baseline visit. Physical functioning was assessed using the Health Assessment Questionnaire (HAQ; scores from 0 (no disability) to 3 (severe disability)). Fatigue was measured using the Functional Assessment of Chronic Illness Therapy (FACIT; scores from 0-52, lower scores representing more fatigue). Depressive symptoms were assessed using the Patient Health Questionnaire (PHQ-9; scores from 0-27, higher scores representing worse symptoms). The PROMIS Short Form v1.0 – Fatigue 8a and the Medical Outcomes Trust Short Form-36 (SF-36) were used to assess sleep quality and HRQoL, respectively. Both are norm based, with mean scores of 50 and standard deviations (SD) of 10 (PROMIS, higher scores representing worse sleep quality; SF-36, lower scores representing worse HRQoL). Disease activity was measured by the recruiting physician using a numerical rating scale ranging from 0 (no activity) to 10 (maximum severity). Multivariate linear regression models were generated to determine the association between disease activity and PROs.

Results: The study included 72 AIM subjects (71% female, mean age 53 years, mean disease duration 0.8 years) with dermatomyositis (49%), overlap myositis (47%) and immune-mediated necrotizing myopathies (4%) (Table 1). Half of the subjects had interstitial lung disease, 29% dysphagia and 19% arthritis. Baseline median (IQR) disease activity was 3 (2-5). 

PRO results are presented in Table 2. Median (IQR) HAQ score was 1 (0.3-1.6) indicating moderate disability. Median (IQR) FACIT scores was 28 (19-40). Mean (SD) PROMIS score was 57 (10), indicating substantially worse sleep quality compared with the general population. Median (IQR) PHQ-9 score was 10 (6-16). The mean (SD) SF-36 physical and mental component summary scores were 1.5 SD (35 (11)) and almost 1 SD (42 (15)) below that of the general population, respectively. Multivariate linear regression analyses (Table 3) showed a statistically significant association between disease activity and worse physical functioning measured with the HAQ (β 0.17, 95%CI 0.09, 0.26), more fatigue measured with the FACIT (β -2.41, 95%CI -3.81, -1.01) and impaired physical HRQoL measured with the SF-36 PCS (β -1.77, 95%CI -3.05, -0.48).

Conclusion: Early AIM subjects feel and function poorly. Impairments in PROs for which standards exist, in particular function, sleep quality and HRQoL, are large, in some cases exceeding 1 SD. There is a need to standardize fatigue and depressive measures to better understand those results. Further research into correlates of and trajectories in PROs in AIM are urgently needed.


Disclosure: V. Leclair, None; B. Thombs, None; M. Wang, None; E. Vinet, None; A. Albert, None; M. Hudson, None.

To cite this abstract in AMA style:

Leclair V, Thombs B, Wang M, Vinet E, Albert A, Hudson M. Patient-reported Outcomes in Early Autoimmune Inflammatory Myopathies [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/patient-reported-outcomes-in-early-autoimmune-inflammatory-myopathies/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-reported-outcomes-in-early-autoimmune-inflammatory-myopathies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology